<DOC>
	<DOC>NCT02424019</DOC>
	<brief_summary>This study will assess the safety in patients treated with ILUVIEN, with primary focus on IOP.</brief_summary>
	<brief_title>Phase 4 IOP Signals Associated With ILUVIENÂ®</brief_title>
	<detailed_description>The specific objectives include the study of intraocular pressure (IOP) related data in patients who received ILUVIEN and how it relates to the patient's experiences following prior treatment with a course of corticosteroid which did not result in a clinically significant IOP elevation.</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Fluocinolone Acetonide</mesh_term>
	<criteria>Patients who are eligible for treatment with ILUVIEN based on the Prescribing Information. Patients who are unable to understand and sign the Informed Consent Form.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>